60 Degrees Pharmaceuticals, Inc. (SXTPW) stock
SXTPWNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as SXTP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 8/3033% below fair value
$0.03−0.00 (-0.38%)
Close on Oct 30, 2026Market cap $3.31MP/E –Yield –
60 Degrees Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
60 Degrees Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$8.55M. For fiscal 2025 it was -$7.72M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$7.72M | – |
| FY2024 | Dec 31, 2024 | -$9.70M | – |
| FY2023 | Dec 31, 2023 | -$5.13M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$2.25M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.08M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.90M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.31M | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.60M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.90M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.06M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.11M | – |
| Q2 FY2024 | Jun 30, 2024 | -$4.19M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.34M | – |